Streetbeat News

Analyst Ratings

WLK

RBC Capital analyst Arun Viswanathan maintains a 'Sector Perform' rating on Westlake (NYSE:WLK) and raises the price target from $127 to $133.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 4:43 pm

EDR

Deutsche Bank analyst Bryan Kraft has maintained a 'Buy' rating on Endeavor Group Holdings (NYSE:EDR) but lowered the price target from $35 to $33.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 4:39 pm

DKNG

Deutsche Bank analyst Carlo Santarelli has maintained a 'Hold' rating on DraftKings (NASDAQ:DKNG) and raised the price target from $24 to $27.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 4:36 pm

ENB

RBC Capital analyst Robert Kwan has maintained an 'Outperform' rating on Enbridge (NYSE:ENB) but lowered the price target from C$65 to C$60.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 4:34 pm

TRHC

William Blair analyst Ryan Daniels has downgraded Tabula Rasa HealthCare (NASDAQ:TRHC) from Outperform to Market Perform.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 4:33 pm

SOVO

Needham analyst Matt McGinley has downgraded Sovos Brands (NASDAQ:SOVO) from Buy to Hold.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 4:32 pm

GTBP

EF Hutton analyst Tony Butler has reiterated a 'Hold' rating on GT Biopharma (NASDAQ:GTBP) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 4:31 pm

MCD

A significant amount of unusual options activity has been observed for McDonald's (NYSE:MCD), with a majority of investors taking a bearish stance. The price range targeted by these investors over the last three months is from $240.0 to $310.0. The current price of MCD is up 1.25% at $290.61. Several financial institutions have maintained their positive ratings on McDonald's, with price targets ranging from $315 to $343.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 4:30 pm

NKTR

Mizuho analyst Mara Goldstein has reiterated a Neutral rating on Nektar Therapeutics (NASDAQ:NKTR) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 4:30 pm

KRYS

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Krystal Biotech (NASDAQ:KRYS) and maintained a price target of $139.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 4:29 pm